Dosing of Enoxaparin and Dalteparin for Anticoagulation in Cancer

Recommended Dosing Regimens

The National Comprehensive Cancer Network recommends dalteparin dosing at 200 units/kg SC daily for 30 days, then reduced to 150 units/kg once daily for extended treatment, while enoxaparin should be dosed at 1 mg/kg SC every 12 hours (or 0.8 mg/kg SC every 12 hours for patients with BMI ≥40 kg/m²) 1, 2, 3
Initial treatment with dalteparin: 200 units/kg SC daily for 30 days, with a Category 1 recommendation (highest level of evidence) for treatment of DVT/PE in cancer patients 1, 4
Extended treatment with dalteparin: Reduce to 150 units/kg SC daily after first month, with dalteparin being the only LMWH specifically FDA-approved for extended treatment of symptomatic VTE in cancer patients 2, 3
Standard dosing of enoxaparin: 1 mg/kg SC every 12 hours, with alternative dosing of 1.5 mg/kg SC once daily potentially considered, though twice-daily dosing may be more efficacious 2, 5

For enoxaparin in severe renal insufficiency (CrCl <30 mL/min): Dose reduction required due to 2-3 fold increased bleeding risk 2, 3
For dalteparin in renal impairment: May be sufficiently cleared but monitoring of peak anti-Xa levels is recommended in patients with CrCl <30 mL/min 2, 3

Dalteparin has been found to be more effective than warfarin for preventing recurrent VTE (8.0% vs 15.8%; HR, 0.48; P=0.002) without increasing bleeding risk 2, 3
Enoxaparin has demonstrated efficacy compared to warfarin with lower rates of combined outcomes including major bleeding or recurrent VTE (10.5% vs 21.1%) 2, 3

Extended anticoagulation therapy with LMWHs is recommended for cancer patients with VTE, with the European Society for Medical Oncology (ESMO) recommending using 75%-80% of the initial dose of LMWH for extended anticoagulation therapy 1, 2, 3, 4
After the initial treatment period, dalteparin dosing should be lowered from 200 units/kg daily to 150 units/kg daily 2, 3

Despite both being LMWHs, dalteparin has the highest quality evidence supporting its use in cancer patients and is the only LMWH FDA-approved specifically for cancer-associated VTE 1, 3
Institutions should develop LMWH dosing algorithms tailored for special populations (renal insufficiency, obesity, low weight, elderly) 2, 3
Regular monitoring of CBC, renal function, and signs of bleeding is essential during treatment 4

The American Society of Clinical Oncology (ASCO) recommends continuing low molecular weight heparin (LMWH) indefinitely for patients with stage IV adenocarcinoma and pulmonary embolism, as long as the cancer remains active, with a strength of evidence based on high-quality clinical trials 6, 7
The initial treatment phase involves starting therapeutic-dose LMWH immediately, with weight-adjusted dosing, such as dalteparin 200 U/kg SC once daily or enoxaparin 1 mg/kg SC every 12 hours, to prevent thrombus extension and fatal pulmonary embolism, based on guidelines from the American College of Chest Physicians 6, 8, 9
For long-term treatment, LMWH should be continued for a minimum of 6 months as the preferred anticoagulant over vitamin K antagonists, with a reduction in dalteparin dose to 150 U/kg SC daily after the first month, as recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) 6, 7, 10, 11
LMWH reduces venous thromboembolism (VTE) recurrence by approximately 50% compared to warfarin, with a recurrence rate of 9% vs 17%, according to the Association of Italian Medical Oncology (AIOM) 12, 9

The French drug agency (ANSM) recommends continuing LMWH beyond 6 months if well tolerated and cancer persists, with regular reassessment of bleeding risk, particularly in elderly patients and those with intracranial malignancy, as suggested by the American College of Cardiology 10, 11, 6
Monitoring considerations beyond 6 months include regular checks of renal function, with consideration of unfractionated heparin (UFH) with monitoring or dose-adjusted LMWH with anti-Xa levels if creatinine clearance falls below 25-30 mL/min, based on guidelines from the International Society on Thrombosis and Haemostasis 12, 9

LMWH can only be discontinued when cancer achieves complete remission or resolution, the patient completes curative treatment with no evidence of active disease, or unacceptable bleeding complications develop that outweigh thrombosis risk, as recommended by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) 10, 11, 12, 6